HRMY
NASDAQHarmony Biosciences Holdings Inc.
Price$32.41+0.05 (+0.14%)
01:30 PM07:45 PM
News · 26 weeks56+117%
2025-12-142026-06-07
Mix3290d
- Insider14(44%)
- SEC Filings10(31%)
- Other4(13%)
- Leadership2(6%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- PRHarmony Biosciences to Participate in Upcoming Investor ConferencesHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for
- INSIDERSEC Form 4 filed by Director Germano Geno J4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 3 filed by new insider Germano Geno J3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Szyper Linda M4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf R. Mark4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Sabater Juan A.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Director Sender Gary4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Budur Kumar converted options into 18,750 shares and covered exercise/tax liability with 8,882 shares, increasing direct ownership by 69% to 24,115 units (SEC Form 4) (for withholding tax)4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF FINANCIAL OFFICER Reicin Glenn4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reicin Glenn3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECSEC Form 144 filed by Harmony Biosciences Holdings Inc.144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECSEC Form 10-Q filed by Harmony Biosciences Holdings Inc.10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic PrioritiesWAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026 Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timefra
- PRHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien
- PRHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual MeetingHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is currently enrolling, and more information about the trial can be found at argustrial.com. Poster presentation details are listed below: Abstract Title: ARGUS: A Study of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Participants with Dravet Syndrome (DS): Preliminary Results from the Open-lab
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Appoints Glenn Reicin as Chief Financial OfficerCOMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies, guiding them through key growth inflection points. With his experience as a sell-side analyst, investor and biotech CFO, he brings
- INSIDERSEC Form 4 filed by Zaeske Adam H.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Anastasiou Peter4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Ignelzi Troy A.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
HRMY FAQ
7 questionsWhat does Harmony Biosciences Holdings Inc. do?
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.Where does HRMY stock trade?
Harmony Biosciences Holdings Inc. (HRMY) is listed on NASDAQ.What sector and industry is HRMY in?
Harmony Biosciences Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Harmony Biosciences Holdings Inc. go public?
Harmony Biosciences Holdings Inc. (HRMY) completed its IPO in 2020.What are analysts saying about HRMY?
Harmony Biosciences Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Hold on 2026-02-23. Recent price targets range from $3300.00 to $4800.00.What companies are similar to HRMY?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare HRMY side-by-side with any of them on Quantisnow.How can I track HRMY on Quantisnow?
Quantisnow aggregates Harmony Biosciences Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HRMY to receive live email and push alerts on every new disclosure.